BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/18/2022 6:01:39 AM | Browse: 615 | Download: 1528
 |
Received |
|
2022-01-07 05:08 |
 |
Peer-Review Started |
|
2022-01-07 05:09 |
 |
First Decision by Editorial Office Director |
|
2022-03-09 04:56 |
 |
Return for Revision |
|
2022-03-10 04:15 |
 |
Revised |
|
2022-03-24 22:59 |
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2022-08-01 03:08 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2022-08-05 21:38 |
 |
Articles in Press |
|
2022-08-05 21:38 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2022-08-09 09:34 |
 |
Publish the Manuscript Online |
|
2022-08-18 06:01 |
| ISSN |
2220-3230 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Systematic Reviews |
| Article Title |
Gastrointestinal manifestations, risk factors, and management in patients with post-transplant lymphoproliferative disorder: A systematic review
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
William Reiche, Abubakar Tauseef, Ahmed Sabri, Mohsin Mirza, David Cantu, Peter Silberstein and Saurabh Chandan |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
William Reiche, Consultant, Doctor, Doctor, Department of Medicine, CHI Creighton University Medical Center, 7500 Mercy Road, Omaha, NE 68124, United States. reichewilliam@gmail.com |
| Key Words |
Post-transplant lymphoproliferative disorder; Gastrointestinal manifestations; Reduction of immunosuppression; Risk factors; Epstein-Barr virus |
| Core Tip |
Patients with a history of solid-organ or hematopoietic stem cell transplantation are at an increased risk of developing post-transplant lymphoproliferative disorder (PTLD). The gastrointestinal (GI) tract is commonly affected as it has an abundance of B and T-cells. GI tract manifestations may be nonspecific; therefore, consideration of risk factors is crucial for identifying GI-PTLD. Like other lymphoma variants, PTLD is very aggressive making early diagnosis key to prognosis. Initial treatment is reduction of immunosuppression which is effective in more than 50% of cases; however, additional therapy including surgery and chemotherapy may also be required. We performed a systematic review of GI-PTLD to better describe GI manifestations, risk factors for disease, and management of GI-PTLD. |
| Publish Date |
2022-08-18 06:01 |
| Citation |
Reiche W, Tauseef A, Sabri A, Mirza M, Cantu D, Silberstein P, Chandan S. Gastrointestinal manifestations, risk factors, and management in patients with post-transplant lymphoproliferative disorder: A systematic review. World J Transplant 2022; 12(8): 268-280 |
| URL |
https://www.wjgnet.com/2220-3230/full/v12/i8/268.htm |
| DOI |
https://dx.doi.org/10.5500/wjt.v12.i8.268 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.